Drug Profile
Dihydrolenperone
Latest Information Update: 10 Mar 2003
Price :
$50
*
At a glance
- Originator Aventis
- Class Antineoplastics; Butyrophenones
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 31 May 2001 No Development Reported - phase unspecified for Cancer in USA